Aurinia Pharmaceuticals Inc. (AUPH)
| Market Cap | 2.09B |
| Revenue (ttm) | 283.06M |
| Net Income (ttm) | 287.20M |
| Shares Out | 129.94M |
| EPS (ttm) | 2.07 |
| PE Ratio | 7.91 |
| Forward PE | 20.13 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 493,906 |
| Open | 16.44 |
| Previous Close | 16.37 |
| Day's Range | 16.10 - 16.62 |
| 52-Week Range | 7.29 - 16.88 |
| Beta | 1.52 |
| Analysts | Buy |
| Price Target | 17.25 (+7.08%) |
| Earnings Date | May 7, 2026 |
About AUPH
Aurinia Pharmaceuticals Inc., a biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan. The company offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. It also develops aritinercept, a dual inhibitor of B cell-activating factor and proliferation-inducing ligand for the potential treatment of autoimmune diseases. The company was founded in 1993 and is headquartered in Edmonton, Can... [Read more]
Financial Performance
In 2025, Aurinia Pharmaceuticals's revenue was $283.06 million, an increase of 20.38% compared to the previous year's $235.13 million. Earnings were $287.20 million, an increase of 4893.08%.
Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for AUPH stock is "Buy." The 12-month stock price target is $17.25, which is an increase of 7.08% from the latest price.
News
Aurinia Pharmaceuticals to Acquire Kezar Life Sciences for $6.955 in Cash per Share Plus a Contingent Value Right
ROCKVILLE, Maryland & EDMONTON, Alberta & SOUTH SAN FRANCISCO, California--(BUSINESS WIRE)--Aurinia Pharmaceuticals to Acquire Kezar Life Sciences for $6.955 in Cash per Share Plus a Contingent Value ...
MKT Capital Applauds Aurinia Pharmaceuticals' Management Transition
CAYMAN ISLANDS--(BUSINESS WIRE)--MKT Capital Ltd. (together with its affiliates, “MKT Capital” or “we”), a significant long-term shareholder of Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (“Aurinia” o...
Why Aurinia Pharmaceuticals Stock Is Surging Monday Morning
The company said Kevin Tang, Aurinia's chair of the board, will succeed Peter Greenleaf as CEO, while Greenleaf will remain on as a consultant to support the transition.
Aurinia Announces Management Transition
ROCKVILLE, Maryland & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Announces Management Transition.
Aurinia Pharmaceuticals (AUPH) Stock Drops After Strong Quarter, Softer Forward Revenue Targets
Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) shares are trading lower Thursday afternoon after the lupus-focused drugmaker posted fourth quarter earnings and raised expectations for continued growth in ...
Aurinia Pharmaceuticals Earnings Call Transcript: Q4 2025
LUPKYNIS sales grew 25% year-over-year in 2025, driving a 20% revenue increase and a dramatic rise in net income, aided by a significant tax benefit. 2026 guidance projects continued double-digit growth, with new clinical programs advancing and competition expected to expand the market.
Aurinia Pharmaceuticals Reports Financial Results for the Three and Twelve Months Ended December 31, 2025 and Provides Update on Recent Business Progress
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced financial results for the three and twelve months ended December 31, 2025 and provided ...
Aurinia Pharmaceuticals to Report Financial Results for the Three and Twelve Months Ended December 31, 2025 and Provide Update on Recent Business Progress on February 26, 2026
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced that it will report financial results for the three and twelve months ended December 31...
Aurinia Pharmaceuticals Earnings Call Transcript: Q3 2025
LUPKYNIS sales surged 27% year-over-year in Q3 2025, prompting a second upward revision of 2025 guidance. New clinical data reinforced LUPKYNIS's efficacy and safety, while Aritinercept advanced toward clinical studies in two autoimmune diseases.
Aurinia Pharmaceuticals Reports Financial Results for the Three and Nine Months Ended September 30, 2025 and Provides Update on Recent Business Progress
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced financial results for the three and nine months ended September 30, 2025, and provided ...
Aurinia Pharmaceuticals to Report Financial Results for the Three and Nine Months Ended September 30, 2025 and Provide Update on Recent Business Progress on November 4, 2025
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced that it will report financial results for the three and nine months ended September 30,...
Aurinia Announces Upcoming Presentations of New Data on LUPKYNIS® at American College of Rheumatology Convergence and American Society of Nephrology Kidney Week 2025
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Announces Upcoming Presentations of New Data on LUPKYNIS® at ACR Convergence and ASN Kidney Week 2025.
Aurinia Responds to Now Retracted LinkedIn Post
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Responds to Now Retracted LinkedIn Post.
Aurinia Pharmaceuticals Earnings Call Transcript: Q2 2025
Q2 2025 saw 22% revenue growth and a sharp rise in net income, driven by LUPKYNIS sales and operational efficiency. Full-year guidance was raised, and positive Aritinercept phase I results support further clinical expansion.
Aurinia Pharmaceuticals Reports Financial Results for the Three and Six Months Ended June 30, 2025
ROCKVILLE, Md.& EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals Reports Financial Results for the Three and Six Months Ended June 30, 2025.
Aurinia Pharmaceuticals to Release Second Quarter 2025 Financial and Operational Results on July 31, 2025
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals to Release Second Quarter 2025 Financial and Operational Results on July 31, 2025.
Aurinia Pharmaceuticals Transcript: Study Result
Aritinercept's phase I study showed strong safety and robust, lasting reductions in immunoglobulins, supporting once-monthly dosing. The drug demonstrated superior potency and binding affinity versus competitors, and further studies in autoimmune diseases are planned for later this year.
Aurinia Announces Positive Results from Phase 1 Study of Aritinercept (AUR200)
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Announces Positive Results from Phase 1 Study of Aritinercept (AUR200).
Aurinia Pharmaceuticals to Host Conference Call to Discuss AUR200 Phase 1 Study Results on June 30, 2025
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals to Host Conference Call to Discuss AUR200 Phase 1 Study Results on June 30, 2025.
New AURORA 1 Analysis: LUPKYNIS-Based Triple Immunosuppressive Therapy Yields Deep Proteinuria Reduction in Lupus Nephritis
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--New AURORA 1 Analysis: LUPKYNIS-Based Triple Immunosuppressive Therapy Yields Deep Proteinuria Reduction in Lupus Nephritis.
Aurinia Pharma Swings Into Profit As Q1 Sales Jumps 24%, Sticks To Guidance
Aurinia Pharmaceuticals Inc. AUPH reported first-quarter earnings of 16 cents per share, compared to a loss of 7 cents a year ago. This beat the consensus of 10 cents.
Aurinia Pharmaceuticals Earnings Call Transcript: Q1 2025
Q1 2025 saw 24% revenue growth and a return to profitability, driven by Lupkynis sales and operational efficiency. Guidance for 2025 is reaffirmed, with continued focus on Lupkynis growth, patent defense, and upcoming AUR-200 phase I data.
Aurinia Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2025
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2025.
Aurinia Pharmaceuticals to Release First Quarter 2025 Financial and Operational Results on May 12, 2025
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals to Release First Quarter 2025 Financial and Operational Results on May 12, 2025.
Glass Lewis Recommends That Aurinia Shareholders Vote “FOR” All Proposals at 2025 Annual General Meeting
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Glass Lewis recommends that Aurinia Shareholders vote “FOR” all proposals at 2025 Annual General Meeting.